{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:13:03Z","timestamp":1773738783791,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":2146,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.virol.2007.02.041","type":"journal-article","created":{"date-parts":[[2007,5,12]],"date-time":"2007-05-12T07:13:13Z","timestamp":1178953993000},"page":"84-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate"],"prefix":"10.1016","volume":"366","author":[{"given":"Patricia L.","family":"Earl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Americo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda S.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leigh","family":"Anne Eller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russ","family":"Byrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Piatak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey D.","family":"Lifson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama","family":"Rao Amara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriet L.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Huggins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Moss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2007.02.041_bib1","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1073\/pnas.98.4.1781","article-title":"The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals","volume":"98","author":"Addo","year":"2001","journal-title":"Proc. Natl. Acad Sci. U.S.A."},{"key":"10.1016\/j.virol.2007.02.041_bib2","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1128\/JVI.79.10.6260-6271.2005","article-title":"Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R","volume":"79","author":"Aldaz-Carroll","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.virol.2005.07.006","article-title":"Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene","volume":"341","author":"Aldaz-Carroll","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.virol.2007.02.041_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1126\/science.274.5284.94","article-title":"Phenotypic analysis of antigen-specific T lymphocytes","volume":"274","author":"Altman","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.virol.2007.02.041_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.292.5514.69","article-title":"Control of a mucosal challenge and prevention of AIDS in rhesus macaques by a multiprotein DNA\/MVA vaccine","volume":"292","author":"Amara","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.virol.2007.02.041_bib6","doi-asserted-by":"crossref","first-page":"6138","DOI":"10.1128\/JVI.76.12.6138-6146.2002","article-title":"Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime\/recombinant modified vaccinia virus Ankara vaccine","volume":"76","author":"Amara","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib7","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.1128\/JVI.76.15.7625-7631.2002","article-title":"Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA\/MVA vaccines","volume":"76","author":"Amara","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/viro.1998.9123","article-title":"The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses","volume":"244","author":"Antoine","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.virol.2007.02.041_bib9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1083\/jcb.146.1.113","article-title":"Intracellular localization of proteasomal degradation of a viral antigen","volume":"146","author":"Anton","year":"1999","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.virol.2007.02.041_bib10","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1128\/JVI.75.5.2462-2467.2001","article-title":"Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys","volume":"75","author":"Barouch","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib11","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1128\/JVI.75.11.5151-5158.2001","article-title":"Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination","volume":"75","author":"Barouch","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib12","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.4049\/jimmunol.172.10.6290","article-title":"Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity","volume":"172","author":"Barouch","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2007.02.041_bib13","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib14","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1016\/S0264-410X(01)00002-0","article-title":"Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian\/human immunodeficiency virus (SHIV89.6P)","volume":"19","author":"Cafaro","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2007.02.041_bib15","first-page":"365","article-title":"Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in nonhuman mammalian cell line","volume":"244","author":"Carroll","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.virol.2007.02.041_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-0684.2005.00128.x","article-title":"Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS","volume":"34","author":"Cline","year":"2005","journal-title":"J. Med. Primatol."},{"key":"10.1016\/j.virol.2007.02.041_bib17","doi-asserted-by":"crossref","first-page":"10199","DOI":"10.1128\/JVI.73.12.10199-10207.1999","article-title":"Characterization of primary isolate-like variants of simian-human immunodeficiency virus","volume":"73","author":"Crawford","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.cell.2006.02.005","article-title":"The rational design of an AIDS vaccine","volume":"124","author":"Douek","year":"2006","journal-title":"Cell"},{"issue":"Pt 2","key":"10.1016\/j.virol.2007.02.041_bib19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1099\/0022-1317-79-2-347","article-title":"Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells","volume":"79","author":"Drexler","year":"1998","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib20","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1128\/jvi.64.5.2448-2451.1990","article-title":"Removal of cryptic poxvirus transcription termination signals from the human immunodediciency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus","volume":"64","author":"Earl","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib21","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1128\/JVI.75.2.645-653.2001","article-title":"Immunogenicity and protective efficacy of oligomeric human immunodeficiency virustType 1 gp140","volume":"75","author":"Earl","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1006\/viro.2001.1345","article-title":"Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model","volume":"294","author":"Earl","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.virol.2007.02.041_bib23","doi-asserted-by":"crossref","first-page":"10684","DOI":"10.1128\/JVI.77.19.10684-10688.2003","article-title":"Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein","volume":"77","author":"Earl","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.virol.2007.02.041_bib25","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1086\/427265","article-title":"Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge","volume":"191","author":"Edghill-Smith","year":"2005","journal-title":"J. Infect Dis."},{"key":"10.1016\/j.virol.2007.02.041_bib26","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1089\/aid.2004.20.989","article-title":"Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes","volume":"20","author":"Egan","year":"2004","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.virol.2007.02.041_bib27","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1126\/science.296.5573.1594","article-title":"Bioterrorism. In search of a kinder, gentler vaccine","volume":"296","author":"Enserink","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.virol.2007.02.041_bib59","series-title":"Smallpox and its eradication","author":"Fenner","year":"1988"},{"key":"10.1016\/j.virol.2007.02.041_bib28","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1586\/14760584.3.4.S75","article-title":"Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors","volume":"3","author":"Franchini","year":"2004","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.virol.2007.02.041_bib29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/375825","article-title":"Smallpox vaccination: a review: Part II. Adverse events","volume":"37","author":"Fulginiti","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virol.2007.02.041_bib30","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/S0264-410X(02)00258-X","article-title":"A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV\/HIV vaccine","volume":"20","author":"Hel","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2007.02.041_bib31","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1126\/science.283.5406.1279","article-title":"The looming threat of bioterrorism","volume":"283","author":"Henderson","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.virol.2007.02.041_bib32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/1568005054201508","article-title":"Non-human primate models for AIDS vaccine research","volume":"5","author":"Hu","year":"2005","journal-title":"Curr. Drug Targets-Infect. Dis."},{"key":"10.1016\/j.virol.2007.02.041_bib33","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1128\/jvi.71.6.4218-4225.1997","article-title":"Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys","volume":"71","author":"Karlsson","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib34","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3201\/eid0807.020032","article-title":"Smallpox research activities: U.S. interagency collaboration, 2001","volume":"8","author":"LeDuc","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.virol.2007.02.041_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev.med.54.101601.152349","article-title":"Progress toward an HIV vaccine","volume":"56","author":"Letvin","year":"2005","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.virol.2007.02.041_bib36","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1073\/pnas.051630798","article-title":"Intralymphatic immunization enhances DNA vaccination","volume":"98","author":"Maloy","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.virol.2007.02.041_bib37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1566524033479799","article-title":"Defining the protective antibody response for HIV-1","volume":"3","author":"Mascola","year":"2003","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.virol.2007.02.041_bib38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01641272","article-title":"Abstammung, eigenschaften und verwendung des attenuieten vaccinia-stammes MVA","volume":"3","author":"Mayr","year":"1975","journal-title":"Infection"},{"key":"10.1016\/j.virol.2007.02.041_bib39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01641272","article-title":"Passage history, properties, and applicability of the attenuated vaccinia virus strain MVA","volume":"3","author":"Mayr","year":"1975","journal-title":"Infection"},{"issue":"Pt 5","key":"10.1016\/j.virol.2007.02.041_bib40","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"Meyer","year":"1991","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib41","doi-asserted-by":"crossref","first-page":"11341","DOI":"10.1073\/pnas.93.21.11341","article-title":"Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety","volume":"93","author":"Moss","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2007.02.041_bib63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.virol.2007.04.010","article-title":"DNA\/MVA HIV-1\/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge","volume":"366","author":"Nigam","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.virol.2007.02.041_bib42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ni762","article-title":"Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo","volume":"3","author":"Norbury","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.virol.2007.02.041_bib43","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1016\/j.vaccine.2005.08.017","article-title":"Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation","volume":"24","author":"Otten","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2007.02.041_bib44","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1128\/JVI.74.6.2740-2751.2000","article-title":"Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) gag-Pol and\/or env in macaques challenged with pathogenic SIV","volume":"74","author":"Ourmanov","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib45","doi-asserted-by":"crossref","first-page":"10200","DOI":"10.1128\/JVI.79.16.10200-10209.2005","article-title":"Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies","volume":"79","author":"Peng","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib46","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.vaccine.2005.07.072","article-title":"Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model","volume":"24","author":"Rao","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2007.02.041_bib47","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1128\/jvi.70.10.6922-6928.1996","article-title":"A chimeric simian\/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys","volume":"70","author":"Reimann","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib48","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1089\/104454902760330174","article-title":"Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses","volume":"21","author":"Richardson","year":"2002","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.virol.2007.02.041_bib49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/415331a","article-title":"Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity","volume":"415","author":"Shiver","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.virol.2007.02.041_bib50","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1089\/088922201750236997","article-title":"HIV-specific cytotoxic T lymphocytes, HLA-A11, and chemokine-related factors may act synergistically to determine HIV resistance in CCR5 delta32-negative female sex workers in Chiang Rai, northern Thailand","volume":"17","author":"Sriwanthana","year":"2001","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.virol.2007.02.041_bib51","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1055\/s-0028-1108143","article-title":"[MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]","volume":"99","author":"Stickl","year":"1974","journal-title":"Dtsch. Med. Wochenschr."},{"key":"10.1016\/j.virol.2007.02.041_bib52","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1016\/S0264-410X(01)00075-5","article-title":"Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques","volume":"19","author":"Stittelaar","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2007.02.041_bib53","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1128\/JVI.79.12.7845-7851.2005","article-title":"Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus","volume":"79","author":"Stittelaar","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2007.02.041_bib54","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1006\/viro.1998.9549","article-title":"Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins","volume":"254","author":"Sugiura","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.virol.2007.02.041_bib55","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2007.02.041_bib56","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/0264-410X(94)90341-7","article-title":"A recombinant vector derived from the host-range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus","volume":"12","author":"Sutter","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2007.02.041_bib57","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00126334-200502010-00002","article-title":"Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV","volume":"38","author":"Van Rompay","year":"2005","journal-title":"J. Acquired Immune Defic. Syndr."},{"key":"10.1016\/j.virol.2007.02.041_bib58","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1073\/pnas.181123498","article-title":"Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine","volume":"98","author":"Wang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2007.02.041_bib60","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1073\/pnas.0401165101","article-title":"Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge","volume":"101","author":"Wyatt","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2007.02.041_bib61","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.virol.2006.01.043","article-title":"Immunization with HIV-1 SF162-derived envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection","volume":"349","author":"Xu","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.virol.2007.02.041_bib62","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1038\/labinvest.3780373","article-title":"The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis)","volume":"81","author":"Zaucha","year":"2001","journal-title":"Lab. Invest."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682207002528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682207002528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T23:49:38Z","timestamp":1758584978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682207002528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S0042682207002528"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2007.02.041","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2007.02.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}